Cyramza 10 mg/ml concentrate for solution for infusion

DRUG8 trials

Sponsors

Daiichi Sankyo Inc., AstraZeneca AB, Alx Oncology Inc., Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH, Fondation Franc.Cancerologie Digestive

Conditions

Advanced/Metastatic Gastric cancerGastric cancerGastroesophageal Junction Adenocarcinoma Expressing Claudin18.2Metastatic Gastric AdenocarcinomaNSQ NSCLCPatients with HER2-overexpressing advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on or after a prior HER2-directed agent and fluoropyrimidine- or platinum-containing chemotherapy (2nd-line or 3rd-line)Progressive well-differentiated metastatic neuroendocrine tumors of the pancreasSQ

Phase 1

A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants with Advanced or Metastatic Non-Small Cell Lung Cancer (ALTAIR)

Not yet recruitingCTIS2024-519786-22-01

AstraZeneca ABmetastatic non-small cell lung cancer (NSCLC)

Target: 43Updated: 2026-04-01

Phase 2

A Phase 2/3 Study of ALX148 in Patients with Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06)

Active, not recruitingCTIS2023-509406-30-00

Alx Oncology Inc.Patients with HER2-overexpressing advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on or after a prior HER2-directed agent and fluoropyrimidine- or platinum-containing chemotherapy (2nd-line or 3rd-line)

Start: 2022-01-24Target: 87Updated: 2026-01-22

PRODIGE 55-SOCRATE : A randomized phase II study to evaluate second-line ramucirumab alone or with paclitaxel in older patients with advanced gastric cancer

CompletedCTIS2024-513515-27-00

Fondation Franc.Cancerologie Digestivestomach cancer stage IV with metastases

Start: 2024-07-10End: 2025-09-26Target: 112Updated: 2025-01-20

A multicenter single-arm pilot study of ramucirumab in combination with dacarbazine in patients with progressive well differentiated metastatic pancreatic neuroendocrine tumors

CompletedCTIS2024-515045-42-00

Martin-Luther-Universitaet Halle-WittenbergProgressive well-differentiated metastatic neuroendocrine tumors of the pancreas

Start: 2018-04-23End: 2025-06-06Target: 45Updated: 2024-10-11

A Phase II, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Volrustomig Priming Regimens in Combination with Other Anticancer Agents in Participants with Solid Tumors (eVOLVE 01). Substudy 1: Volrustomig + Chemotherapy as 1L Treatment in Participants with Advanced or Metastatic NSCLC NSQ and PD-L1 TPS xx Substudy 2: Volrustomig + Ramucirumab + Chemotherapy as 1L Treatment in Participants with Advanced or Metastatic NSCLC SQ or NSQ and PD-L1 TPS xx

RecruitingCTIS2023-509482-20-00

AstraZeneca ABNSQ NSCLC, Solid Tumors, SQ

Start: 2024-12-03Target: 91Updated: 2025-10-21

Phase 3

A Phase 3, Multicenter, 2-Arm Randomized, Open-Label Study of Trastuzumab Deruxtecan in Subjects with HER2 Positive Metastatic and/or Unresectable Gastric or Gastro Esophageal Junction (GEJ) Adenocarcinoma Subjects who have Progressed on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Active, not recruitingCTIS2023-507963-20-00

Daiichi Sankyo Inc.Metastatic Gastric Adenocarcinoma

Start: 2021-08-19Target: 213Updated: 2025-11-04

A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared With Investigator’s Choice of Therapy in Second- or Later-Line Adult Participants with Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin 18.2 (CLARITY-Gastric 01)

RecruitingCTIS2023-508276-11-00

AstraZeneca ABAdvanced/Metastatic Gastric cancer, Gastric cancer, Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Start: 2025-01-17Target: 91Updated: 2025-09-15

Ramucirumab plus Irinotecan / Leucovorin / 5-FU versus Ramucirumab plus Paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy - The Phase II/III RAMIRIS STUDY

Active, not recruitingCTIS2024-512934-14-00

Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbHadvanced or metastatic adenocarcinoma of the stomach or gastroesophageal junctions, who failed prior line of palliative chemotherpay

Start: 2016-11-07Target: 319Updated: 2025-06-23